NASDAQ:SYRE Spyre Therapeutics (SYRE) Stock Price, News & Analysis $31.47 +1.36 (+4.52%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$30.24▼$31.5450-Day Range$22.71▼$37.9852-Week Range$8.43▼$47.97Volume372,811 shsAverage Volume526,552 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$43.17 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Spyre Therapeutics alerts: Email Address Spyre Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside37.2% Upside$43.17 Price TargetShort InterestBearish19.59% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.82) to ($3.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector815th out of 936 stocksPharmaceutical Preparations Industry380th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingSpyre Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSpyre Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Spyre Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted19.59% of the float of Spyre Therapeutics has been sold short.Short Interest Ratio / Days to CoverSpyre Therapeutics has a short interest ratio ("days to cover") of 15, which indicates bearish sentiment.Change versus previous monthShort interest in Spyre Therapeutics has recently increased by 16.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpyre Therapeutics does not currently pay a dividend.Dividend GrowthSpyre Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SYRE. Previous Next 2.7 News and Social Media Coverage News SentimentSpyre Therapeutics has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Spyre Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Spyre Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spyre Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.20% of the stock of Spyre Therapeutics is held by insiders.Percentage Held by Institutions80.39% of the stock of Spyre Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Spyre Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Spyre Therapeutics are expected to decrease in the coming year, from ($3.82) to ($3.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spyre Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spyre Therapeutics is -0.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Spyre Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupDave Ramsey Makes Big Mistake Live On AirDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Spyre Therapeutics Stock (NASDAQ:SYRE)Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.Read More SYRE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SYRE Stock News HeadlinesJuly 25 at 10:15 PM | finance.yahoo.comSpyre Therapeutics, Inc. (3920.F)July 17, 2024 | americanbankingnews.comSpyre Therapeutics (NASDAQ:SYRE) Now Covered by Analysts at Evercore ISIJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.June 18, 2024 | prnewswire.comSpyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel DiseaseJune 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 29, 2024 | prnewswire.comSpyre Therapeutics to Participate in the Jefferies Global Healthcare ConferenceMay 15, 2024 | prnewswire.comSpyre Therapeutics Appoints Accomplished Biopharma Leader Dr. Sandra Milligan to its Board of DirectorsMay 14, 2024 | markets.businessinsider.comPositive Outlook on Spyre Therapeutics’ IBD Pipeline and Financial StabilityJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.May 10, 2024 | markets.businessinsider.comSpyre Therapeutics: Strong Buy Recommendation on Robust Pipeline and Financial StabilityMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed: Spyre Therapeutics’ Promising Pipeline and Expert Team Drive Positive OutlookMay 10, 2024 | finanznachrichten.deSpyre Therapeutics, Inc.: Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comSYRE Stock Earnings: Spyre Therapeutics Misses EPS for Q1 2024May 9, 2024 | chron.comSpyre Therapeutics: Q1 Earnings SnapshotMay 9, 2024 | prnewswire.comSpyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 3, 2024 | prnewswire.comSpyre Therapeutics Announces Grants of Inducement AwardsMay 3, 2024 | msn.comBaird Initiates Coverage of Spyre Therapeutics (SYRE) with Outperform RecommendationMay 3, 2024 | msn.comCarvana upgraded, Block downgraded: Wall Street's top analyst callsSee More Headlines Receive SYRE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spyre Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SYRE Previous SymbolNASDAQ:SYRE CUSIPN/A CIK1636282 Webwww.aeglea.com Phone512-942-2935Fax512-872-5121Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$43.17 High Stock Price Target$54.00 Low Stock Price Target$31.00 Potential Upside/Downside+37.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($71.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-338,790,000.00 Net MarginsN/A Pretax Margin-52,933.57% Return on EquityN/A Return on Assets-79.05% Debt Debt-to-Equity RatioN/A Current Ratio11.38 Quick Ratio11.38 Sales & Book Value Annual Sales$890,000.00 Price / Sales1,424.28 Cash FlowN/A Price / Cash FlowN/A Book Value($0.22) per share Price / Book-143.05Miscellaneous Outstanding Shares40,280,000Free Float37,785,000Market Cap$1.27 billion OptionableOptionable Beta2.94 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Cameron Turtle DPHIL (Age 34)Ph.D., CEO & Director Comp: $674.17kMr. Scott L. Burrows (Age 47)Chief Financial Officer Comp: $331.81kMs. Heidy Abreu King-Jones J.D. (Age 41)L.L.M., Chief Legal Officer & Corporate Secretary Comp: $568.87kDr. Janet Gunzner-Toste M.B.A.Ph.D., Senior Vice President of OperationsMr. Brian ConnollyChief Technical OfficerMr. Eric McIntyreVice President of Finance & Investor RelationsMr. James MyersVice President of Quality & ComplianceDr. Kelly Boothe Ph.D.Senior Director of Corporate Communications & Investor RelationsDr. Justin LaFountaine Ph.D.Senior Vice President of Corporate DevelopmentMs. Melissa CooperSenior Vice President of PeopleMore ExecutivesKey CompetitorsApellis PharmaceuticalsNASDAQ:APLSAvidity BiosciencesNASDAQ:RNACrinetics PharmaceuticalsNASDAQ:CRNXImmunovantNASDAQ:IMVTArcellxNASDAQ:ACLXView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 117,686 shares on 7/26/2024Ownership: 0.292%EFG Asset Management North America Corp.Bought 36,781 shares on 7/26/2024Ownership: 0.091%SG Americas Securities LLCBought 5,545 shares on 7/12/2024Ownership: 0.014%View All Institutional Transactions SYRE Stock Analysis - Frequently Asked Questions How have SYRE shares performed this year? Spyre Therapeutics' stock was trading at $21.52 at the start of the year. Since then, SYRE shares have increased by 46.2% and is now trading at $31.47. View the best growth stocks for 2024 here. How were Spyre Therapeutics' earnings last quarter? Spyre Therapeutics, Inc. (NASDAQ:SYRE) announced its quarterly earnings data on Monday, May, 13th. The company reported ($1.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.90) by $0.30. Who are Spyre Therapeutics' major shareholders? Spyre Therapeutics' top institutional shareholders include Bank of New York Mellon Corp (0.29%), EFG Asset Management North America Corp. (0.09%) and SG Americas Securities LLC (0.01%). How do I buy shares of Spyre Therapeutics? Shares of SYRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SYRE) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spyre Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spyre Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SYRE Stock Alerts